Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-News: Relief Reports 2020 Financial Results -2-

04/15/2021 | 01:02am EDT
Throughout 2021 Relief will continue to evaluate and take steps to facilitate interest from institutional investors. In 
addition, the Company expects to "up list" to a major U.S. stock exchange in the coming months. 
Relief's 2020 Annual Report is available for download at https://relieftherapeutics.com/investor-relations. 
### 
ABOUT RELIEF THERAPEUTICS HOLDING AG 
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in 
human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100^TM (aviptadil), a synthetic form 
of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory 
deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a 
Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of 
ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate 
(NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. 
Follow us on LinkedIn 
CONTACT                                                            FOR MEDIA/INVESTOR INQUIRIES: 
RELIEF THERAPEUTICS Holding AG                                     MC Services AG 
Raghuram (Ram) Selvaraju, Ph.D., MBA                               Anne Hennecke / Brittney Sojeva 
Chairman of the Board                                              Tel.: +49 (0) 211-529-252-14 
Mail: contact@relieftherapeutics.com                               Mail: relief@mc-services.eu Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for ACER-001 for the treatment of UCDs and MSUD, nor whether the ongoing clinical trials of Relief's lead compound, RLF-100(TM) (aviptadil) in advanced clinical development to treat respiratory deficiency due to COVID-19, will be successful. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. ----------------------------------------------------------------------------------------------------------------------- 

End of Media Release -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       contact@relieftherapeutics.com 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1184903 
 
End of News   EQS Group News Service 
=------------ 

1184903 2021-04-15

(END) Dow Jones Newswires

April 15, 2021 01:01 ET (05:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ACER THERAPEUTICS INC. -3.08% 2.52 Delayed Quote.-0.76%
DJ INDUSTRIAL 1.29% 34021.45 Delayed Quote.11.97%
RELIEF THERAPEUTICS HOLDING AG 3.92% 0.1855 Delayed Quote.-31.04%
All news about RELIEF THERAPEUTICS HOLDING AG
05/04RELIEF THERAPEUTICS  : Signs Binding Term Sheet To Buy APR Applied Pharma Resear..
MT
05/04RELIEF THERAPEUTICS  : and Applied Pharma Research (APR) Sign Binding Term Sheet..
PU
05/04EQS-NEWS : Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for ..
DJ
04/22RELIEF THERAPEUTICS  : Initiates Phase-Two Trial For Respiratory Distress Syndro..
MT
04/22RELIEF THERAPEUTICS  : and AdVita Announce Initiation of Phase 2 Trial with Inha..
PU
04/22RELIEF THERAPEUTICS  : and AdVita Announce Initiation of Phase 2 Trial with Inha..
EQ
04/19RELIEF THERAPEUTICS  : Swiss pharma firm Relief, U.S. partner fight after hopes ..
RE
04/19RELIEF THERAPEUTICS  : Refutes NeuroRx's Claims Over Collaboration Deal
MT
04/19RELIEF THERAPEUTICS  : Comments on Certain Statements Made by NeuroRx, Inc. in t..
PU
04/19RELIEF THERAPEUTICS  : Comments on Certain Statements Made by NeuroRx, Inc. in t..
EQ
More news
Financials
Sales 2021 260 M 287 M 287 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 626 M 690 M 691 M
Capi. / Sales 2021 2,41x
Capi. / Sales 2022 1,25x
Nbr of Employees 10
Free-Float 47,8%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 0,93 CHF
Last Close Price 0,19 CHF
Spread / Highest target 401%
Spread / Average Target 401%
Spread / Lowest Target 401%
Managers and Directors
NameTitle
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Gilles Della Corte Chief Medical Officer
Jeremy Meinen Vice President-Finance & Administration
Thomas Plitz Director
Sector and Competitors
1st jan.Capitalization (M$)
RELIEF THERAPEUTICS HOLDING AG-31.04%689
MODERNA, INC.46.15%61 305
LONZA GROUP AG-1.83%45 649
IQVIA HOLDINGS INC.27.25%43 699
CELLTRION, INC.-26.88%31 675
SEAGEN INC.-17.34%26 272